REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
09/08/2025
Back to search
Official data from USPTO
OSFIRM THERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
23
Latest update
09/09/2025
Trademark type
Combined
Nice classes
10
Filing date
12/30/2019
Registration date
09/08/2020
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
09/08/2020
Last transaction
09/09/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
03
Owner location
Gyeonggi-do, KR
Examiner
SIMCOX,KYLE DUNCAN
Law office
N40
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the black wording "OSFIRM" above the black wording "THERAPEUTICS", with a red irregular polygon shape above and to the right of the wording "OSFIRM".
Holders and representatives
Holders
Osfirm Co., Ltd.
Representatives
Diane J. Mason Faegre Drinker Biddle & Reath LLP
Technical classification
Nice Classes
Class 10
Vienna Codes
No Vienna codes available.
Goods and services
Class 10
Artificial breast implants; Artificial pectoral implants; breast prostheses; Surgical implants made of artificial materials for osteosynthesis; bone cementation equipment being surgical instruments and apparatus; biodegradable surgical implants made of artificial materials; biodegradable bone fixation implants; silicone surgical implants for cosmetic implantation; Synthetic bone graft substitutes for plastic surgery; medical apparatus and instruments for plastic surgery; medical apparatus and instruments for use in general surgery; medical implants consisting of artificial materials; medical filler apparatusinjection syringes sold empty; surgical implants comprised of artificial materials; medicalsurgical and orthopedic implants made of artificial materials; medical apparatus and instruments for use in surgery; supporters for medical purposes; medical apparatus for introducing pharmaceutical preparations into the human body; osseous implants made of artificial materials; Surgical implants consisting of artificial materials being substitutes for bonescartilageligamentstendons
Publications
History of USPTO decisions and trademark events.
23 publications found
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
01/24/2021
FICS
FINAL DISPOSITION NOTICE SENT TO IB
12/31/2020
FIMP
FINAL DISPOSITION PROCESSED
12/31/2020
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
12/08/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
09/08/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
06/23/2020
PUBO
PUBLISHED FOR OPPOSITION
06/23/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
06/03/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/19/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/19/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/19/2020
ALIE
ASSIGNED TO LIE
05/19/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
05/13/2020
RFNT
REFUSAL PROCESSED BY IB
04/24/2020
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
04/03/2020
RFRR
REFUSAL PROCESSED BY MPU
04/03/2020
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
03/19/2020
CNRT
NON-FINAL ACTION WRITTEN
03/18/2020
DOCK
ASSIGNED TO EXAMINER
03/17/2020
MAFR
APPLICATION FILING RECEIPT MAILED
02/25/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
02/19/2020
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
02/13/2020
Continuous trademark protection
Get notified about every new filing that threatens OSFIRM THERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.